CN103435696B - 修饰抗体的方法和具有改善的功能性质的修饰抗体 - Google Patents
修饰抗体的方法和具有改善的功能性质的修饰抗体 Download PDFInfo
- Publication number
- CN103435696B CN103435696B CN201310383003.3A CN201310383003A CN103435696B CN 103435696 B CN103435696 B CN 103435696B CN 201310383003 A CN201310383003 A CN 201310383003A CN 103435696 B CN103435696 B CN 103435696B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid position
- scfv
- sequence
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Abstract
Description
蛋白质 | 蛋白质丧失(不溶性聚集物) |
ESBA105 | 1.14% |
ESBA105 Opt1_0 | 8.17% |
ESBA105 Opt 0_2 | 4.45% |
ESBA105 Opt 1_2 | 46.60% |
ESBA105 VH V103T | -1.95% |
Claims (2)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93711207P | 2007-06-25 | 2007-06-25 | |
US60/937,112 | 2007-06-25 | ||
US6905608P | 2008-03-12 | 2008-03-12 | |
US61/069,056 | 2008-03-12 | ||
CN200880021889.4A CN101849001B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880021889.4A Division CN101849001B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103435696A CN103435696A (zh) | 2013-12-11 |
CN103435696B true CN103435696B (zh) | 2016-10-12 |
Family
ID=39820887
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610852278.0A Active CN106366192B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN201510357753.2A Pending CN105017427A (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN201310383003.3A Active CN103435696B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN200880021889.4A Active CN101849001B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN202010126672.2A Pending CN111253484A (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN201210317160.XA Active CN102838673B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610852278.0A Active CN106366192B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN201510357753.2A Pending CN105017427A (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880021889.4A Active CN101849001B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN202010126672.2A Pending CN111253484A (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CN201210317160.XA Active CN102838673B (zh) | 2007-06-25 | 2008-06-25 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20090074780A1 (zh) |
EP (1) | EP2158315B1 (zh) |
JP (5) | JP5611820B2 (zh) |
KR (1) | KR101573086B1 (zh) |
CN (6) | CN106366192B (zh) |
AU (1) | AU2008267734B9 (zh) |
BR (1) | BRPI0813645A2 (zh) |
CA (1) | CA2689941C (zh) |
DK (1) | DK2158315T3 (zh) |
ES (1) | ES2566737T3 (zh) |
HK (1) | HK1137483A1 (zh) |
HR (1) | HRP20160730T1 (zh) |
HU (1) | HUE027507T2 (zh) |
IL (1) | IL202360A (zh) |
MX (1) | MX2009013328A (zh) |
NZ (2) | NZ581468A (zh) |
PL (1) | PL2158315T3 (zh) |
RU (3) | RU2540150C2 (zh) |
SI (1) | SI2158315T1 (zh) |
WO (1) | WO2009000099A2 (zh) |
ZA (1) | ZA200908384B (zh) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
CN101222758B (zh) | 2007-01-08 | 2011-10-26 | 中兴通讯股份有限公司 | 一种在高速分组数据网传递1x寻呼被拒绝的方法 |
CN101668771B (zh) | 2007-03-12 | 2013-08-21 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的工程改造和最优化 |
EP2158315B1 (en) | 2007-06-25 | 2016-03-23 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods of modifying antibodies, and modified antibodies with improved functional properties |
EP2164961B1 (en) | 2007-06-25 | 2015-01-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
PT3241843T (pt) | 2008-06-25 | 2021-09-10 | Novartis Ag | Otimização da solubilidade de imunoligantes |
ES2861592T3 (es) | 2008-06-25 | 2021-10-06 | Novartis Ag | Anticuerpos estables y solubles que inhiben el TNF |
CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
EP3722310A1 (en) | 2008-06-25 | 2020-10-14 | Novartis AG | Stable and soluble antibodies inhibiting vegf |
BRPI0915343A2 (pt) * | 2008-06-30 | 2015-10-27 | Esbatech Alcon Biomed Res Unit | polipeptídeos funcionalizados |
AU2010226392B9 (en) | 2009-03-20 | 2014-05-22 | Amgen Inc. | Selective and potent peptide inhibitors of Kv1.3 |
US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
EP2501407A1 (en) | 2009-11-20 | 2012-09-26 | Amgen Inc. | Anti-orai1 antigen binding proteins and uses thereof |
CA2814780C (en) | 2010-09-22 | 2017-05-16 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
NZ610267A (en) | 2010-10-08 | 2015-05-29 | Hope City | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
AU2013203189B2 (en) * | 2010-10-22 | 2014-12-11 | Novartis Ag | Stable and soluble antibodies |
UY33679A (es) * | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
AU2016277637B2 (en) * | 2010-10-22 | 2018-11-08 | Novartis Ag | Stable and soluble antibodies |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP2766382B1 (en) * | 2011-10-10 | 2020-05-06 | City of Hope | Meditopes and meditope-binding antibodies and uses thereof |
AR088403A1 (es) * | 2011-10-20 | 2014-05-28 | Esbatech A Novartis Co Llc | Anticuerpo de union a multiples antigenos estable |
US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
IN2014DN09417A (zh) * | 2012-05-10 | 2015-07-17 | Bioatla Llc | |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
DK2889377T3 (da) | 2012-08-24 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Fc?RIIb-Specifik Fc-regionsvariant |
SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
AU2014301629B2 (en) | 2013-06-26 | 2020-02-06 | Numab Therapeutics AG | Novel antibody frameworks |
CN104341501B (zh) * | 2013-07-29 | 2019-08-30 | 上海睿智化学研究有限公司 | 抗IL-1β人源化单克隆抗体及其制备方法和应用 |
SI3143042T1 (sl) * | 2014-05-16 | 2020-08-31 | Ablynx N.V. | Variabilne domene imunoglobulina |
KR20230145503A (ko) | 2014-05-16 | 2023-10-17 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
CA2960756C (en) | 2014-09-15 | 2023-08-01 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
PE20221834A1 (es) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina |
CA2974547A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof |
AU2016323440B2 (en) | 2015-09-15 | 2023-07-13 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
WO2017106578A1 (en) | 2015-12-15 | 2017-06-22 | Amgen Inc. | Pacap antibodies and uses thereof |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
CA3014001A1 (en) | 2016-02-25 | 2017-08-31 | Cell Medica Switzerland Ag | Binding members to pd-l1 |
MX2019001448A (es) | 2016-08-05 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CA3043528A1 (en) | 2016-11-14 | 2018-05-17 | Amgen Inc. | Bispecific or biparatopic antigen binding proteins and uses thereof |
CA3087951A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
CN112119090B (zh) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
CA3125453A1 (en) * | 2019-01-03 | 2020-07-09 | Amgen Inc. | Engineering monoclonal antibodies to improve stability and production titer |
SG11202112926YA (en) | 2019-05-30 | 2021-12-30 | Amgen Inc | Engineering the hinge region to drive antibody dimerization |
CA3143524A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
AU2020380379A1 (en) | 2019-11-08 | 2022-05-26 | Amgen Inc. | Engineering charge pair mutations for pairing of hetero-IgG molecules |
MX2022005965A (es) | 2019-11-19 | 2022-08-08 | Amgen Inc | Formato de anticuerpos multiespecíficos novedosos. |
CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
MX2023002125A (es) | 2020-08-20 | 2023-04-26 | Amgen Inc | Proteínas de unión a antígenos con disulfuro no canónico en la región fab. |
JP2023544769A (ja) | 2020-10-07 | 2023-10-25 | アムジエン・インコーポレーテツド | 多重特異性抗体の構築のためのビルディングブロックの合理的選択 |
MX2023005379A (es) | 2020-11-10 | 2023-05-23 | Amgen Inc | Enlazadores novedosos de dominios de union a antigenos multiespecificos. |
CN116848136A (zh) | 2021-02-12 | 2023-10-03 | 勃林格殷格翰国际有限公司 | 补体c3抗原结合蛋白 |
WO2022190007A1 (en) | 2021-03-09 | 2022-09-15 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries |
KR20230169944A (ko) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | Mage-a4 펩티드-mhc 항원 결합 단백질 |
JP2024515301A (ja) | 2021-04-20 | 2024-04-08 | アムジエン・インコーポレーテツド | 多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布 |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
WO2023110918A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008451A2 (en) * | 2001-07-19 | 2003-01-30 | Universität Zürich | Modification of human variable domains |
WO2006131013A2 (en) * | 2005-06-07 | 2006-12-14 | Esbatech Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
CN101210241A (zh) * | 2006-12-27 | 2008-07-02 | 陕西超英生物科技有限公司 | 一种噬菌体基因工程抗体库基因组装的方法 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1197800A (en) * | 1983-05-02 | 1985-12-10 | William O. Weigle | Immune modulator peptides |
JP3854306B2 (ja) | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
EP0519596B1 (en) * | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DK0698097T3 (da) * | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6740734B1 (en) * | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
CN103275221B (zh) * | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
AU729035B2 (en) | 1997-06-12 | 2001-01-25 | Novartis Ag | Artificial antibody polypeptides |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
CN100531798C (zh) | 1998-08-11 | 2009-08-26 | 拜奥根Idec公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6602977B1 (en) * | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
DE60012980T2 (de) | 1999-12-28 | 2005-08-18 | Esbatech Ag | Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen |
MXPA02011163A (es) * | 2000-05-10 | 2004-08-19 | Mayo Foundation | Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
HUP0302573A2 (hu) | 2000-10-13 | 2003-10-28 | Biogen, Inc. | Humanizált anti-LT-béta-R ellenanyagok |
GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
DE60236861D1 (de) | 2001-04-26 | 2010-08-12 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
JP2005506833A (ja) * | 2001-06-04 | 2005-03-10 | キュラジェン コーポレイション | 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法 |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
ES2323949T3 (es) | 2001-12-28 | 2009-07-28 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpos anti-fgf-8 para tratar la artritis. |
US6905608B2 (en) | 2002-01-22 | 2005-06-14 | Exergy Technologies Corporation | Advanced electrodeionization for fluid recycling |
US8853362B2 (en) | 2002-05-22 | 2014-10-07 | Esbatech, An Alcon Biomedical Research Unit Llc | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
CN1678625A (zh) | 2002-07-01 | 2005-10-05 | 比奥根艾迪克Ma公司 | 人源化抗淋巴毒素β受体的抗体 |
US7300655B2 (en) | 2002-08-01 | 2007-11-27 | Immunomedics, Inc. | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof |
CN103833854B (zh) * | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
KR100912381B1 (ko) | 2003-06-19 | 2009-08-19 | 타녹스 인코퍼레이티드 | 응고 관련 질병을 치료하기 위한 조성물 및 방법 |
WO2005005604A2 (en) * | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
UY28641A1 (es) * | 2003-11-28 | 2005-06-30 | Astrazeneca Ab | Anticuerpos |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US8039588B2 (en) | 2004-05-21 | 2011-10-18 | The Uab Research Foundation | Variable lymphocyte receptors |
PT2314620E (pt) | 2004-05-27 | 2013-09-02 | Crucell Holland Bv | Método de identificação de moléculas de ligação capazes de neutralizar o vírus da raiva |
GB0416651D0 (en) * | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
CN101171034B (zh) | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
AU2006227536B9 (en) | 2005-03-25 | 2011-08-18 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
CN103665168A (zh) | 2005-06-03 | 2014-03-26 | 持田制药株式会社 | 抗cd14抗体融合蛋白质 |
PL1899377T3 (pl) | 2005-07-05 | 2013-01-31 | Glaxo Group Ltd | Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
NO345919B1 (no) | 2005-08-26 | 2021-10-18 | Roche Glycart Ag | Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet |
JP2009516513A (ja) * | 2005-11-21 | 2009-04-23 | ラボラトワール セローノ ソシエテ アノニム | ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用 |
WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
WO2007070750A1 (en) * | 2005-12-13 | 2007-06-21 | Eli Lilly And Company | Anti-il-17 antibodies |
US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
ES2603399T3 (es) | 2006-07-10 | 2017-02-27 | Esbatech, An Alcon Biomedical Research Unit Llc | Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
CN101668771B (zh) | 2007-03-12 | 2013-08-21 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的工程改造和最优化 |
EP2164961B1 (en) | 2007-06-25 | 2015-01-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
EP2158315B1 (en) * | 2007-06-25 | 2016-03-23 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods of modifying antibodies, and modified antibodies with improved functional properties |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
-
2008
- 2008-06-25 EP EP08757278.0A patent/EP2158315B1/en not_active Revoked
- 2008-06-25 MX MX2009013328A patent/MX2009013328A/es active IP Right Grant
- 2008-06-25 US US12/145,600 patent/US20090074780A1/en not_active Abandoned
- 2008-06-25 AU AU2008267734A patent/AU2008267734B9/en active Active
- 2008-06-25 WO PCT/CH2008/000285 patent/WO2009000099A2/en active Application Filing
- 2008-06-25 SI SI200831598A patent/SI2158315T1/sl unknown
- 2008-06-25 CN CN201610852278.0A patent/CN106366192B/zh active Active
- 2008-06-25 KR KR1020097027049A patent/KR101573086B1/ko active IP Right Grant
- 2008-06-25 NZ NZ581468A patent/NZ581468A/xx not_active IP Right Cessation
- 2008-06-25 ES ES08757278.0T patent/ES2566737T3/es active Active
- 2008-06-25 CN CN201510357753.2A patent/CN105017427A/zh active Pending
- 2008-06-25 JP JP2010513601A patent/JP5611820B2/ja active Active
- 2008-06-25 NZ NZ601946A patent/NZ601946A/en not_active IP Right Cessation
- 2008-06-25 CA CA2689941A patent/CA2689941C/en active Active
- 2008-06-25 CN CN201310383003.3A patent/CN103435696B/zh active Active
- 2008-06-25 CN CN200880021889.4A patent/CN101849001B/zh active Active
- 2008-06-25 CN CN202010126672.2A patent/CN111253484A/zh active Pending
- 2008-06-25 RU RU2010102065/10A patent/RU2540150C2/ru active
- 2008-06-25 BR BRPI0813645-9A2A patent/BRPI0813645A2/pt not_active IP Right Cessation
- 2008-06-25 PL PL08757278.0T patent/PL2158315T3/pl unknown
- 2008-06-25 HU HUE08757278A patent/HUE027507T2/en unknown
- 2008-06-25 CN CN201210317160.XA patent/CN102838673B/zh active Active
- 2008-06-25 DK DK08757278.0T patent/DK2158315T3/en active
-
2009
- 2009-11-26 ZA ZA2009/08384A patent/ZA200908384B/en unknown
- 2009-11-26 IL IL202360A patent/IL202360A/en active IP Right Grant
-
2010
- 2010-04-09 HK HK10103501.4A patent/HK1137483A1/zh unknown
-
2014
- 2014-09-03 JP JP2014178667A patent/JP6129797B2/ja active Active
- 2014-10-22 RU RU2014142680A patent/RU2014142680A/ru not_active Application Discontinuation
-
2016
- 2016-06-23 HR HRP20160730TT patent/HRP20160730T1/hr unknown
-
2017
- 2017-04-12 JP JP2017079036A patent/JP2017186338A/ja active Pending
- 2017-09-12 US US15/701,923 patent/US20190002551A1/en not_active Abandoned
-
2019
- 2019-05-07 JP JP2019087504A patent/JP2019141091A/ja active Pending
- 2019-06-11 RU RU2019118109A patent/RU2019118109A/ru unknown
-
2021
- 2021-05-06 JP JP2021078725A patent/JP2021119782A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008451A2 (en) * | 2001-07-19 | 2003-01-30 | Universität Zürich | Modification of human variable domains |
WO2006131013A2 (en) * | 2005-06-07 | 2006-12-14 | Esbatech Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
CN101210241A (zh) * | 2006-12-27 | 2008-07-02 | 陕西超英生物科技有限公司 | 一种噬菌体基因工程抗体库基因组装的方法 |
Non-Patent Citations (1)
Title |
---|
Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach;Ewert S et al.;《Biochemistry》;20030218;第42卷(第6期);全文 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103435696B (zh) | 修饰抗体的方法和具有改善的功能性质的修饰抗体 | |
CN101688200B (zh) | 单链抗体的基于序列的改造和优化 | |
CN103275216B (zh) | 单链抗体的基于序列的工程改造和最优化 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Swiss Shi Lilun Applicant after: Esbatech Alcon Biomed Res Unit Address before: Swiss Shi Lilun Applicant before: Esbatech Alcon Biomed Res Unit |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ESBATECH, ESBATECH ALCON BIOMEDICAL RESEARCH UNIT LLC TO: ESBATECH-NOVARTIS COMPANY LLC |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20131211 Assignee: Delenex Therapeutics AG Assignor: Esbatech Alcon Biomed Res Unit Contract record no.: 2014990000590 Denomination of invention: Methods of modifying antibodies, and modified antibodies with improved functional properties License type: Common License Record date: 20140724 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210804 Address after: Basel, SUI Patentee after: NOVARTIS AG Address before: Swiss Shi Lilun Patentee before: ESBATech, an Alcon Biomedical Research Unit LLC |